GENFIT Unveils ACLF Pipeline Developments at AASLD Meeting 2025

GENFIT, a biopharmaceutical company, will showcase its latest advancements in the ACLF pipeline at the AASLD Liver Meeting 2025 in Washington, D.C. The company will present data on three ACLF programs, including G1090N, a reformulation of nitazoxanide, which shows promise in systemic inflammation and organ function. Safety and early efficacy data are anticipated by year-end.

Additional presentations will highlight SRT-015, an ASK1 inhibitor, and CLM-022, an NLRP3 inflammasome inhibitor, both of which could significantly impact ACLF treatment. Real-world evidence studies and biomarker research in cirrhosis will also be featured.

Partner Ipsen will present findings on Iqirvo® in PBC and PSC, suggesting its potential in managing rare liver diseases. GENFIT's presence at the meeting underscores its dedication to addressing unmet medical needs in liver disease.